vs
Side-by-side financial comparison of BingEx Ltd (FLX) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
BingEx Ltd is the larger business by last-quarter revenue ($143.2M vs $123.8M, roughly 1.2× NATURES SUNSHINE PRODUCTS INC). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs 2.2%, a 1.1% gap on every dollar of revenue.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
FLX vs NATR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.2M | $123.8M |
| Net Profit | $3.2M | $4.1M |
| Gross Margin | 10.8% | 72.5% |
| Operating Margin | — | 4.3% |
| Net Margin | 2.2% | 3.3% |
| Revenue YoY | — | 4.7% |
| Net Profit YoY | — | 1379.4% |
| EPS (diluted) | — | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $143.2M | — | ||
| Q4 25 | — | $123.8M | ||
| Q3 25 | $141.2M | $128.3M | ||
| Q2 25 | $143.0M | $114.8M | ||
| Q1 25 | $141.0M | $113.2M | ||
| Q4 24 | — | $118.2M | ||
| Q3 24 | $164.6M | $114.6M | ||
| Q2 24 | — | $110.6M |
| Q1 26 | $3.2M | — | ||
| Q4 25 | — | $4.1M | ||
| Q3 25 | $6.1M | $5.3M | ||
| Q2 25 | $7.5M | $5.3M | ||
| Q1 25 | $27.6M | $4.7M | ||
| Q4 24 | — | $-321.0K | ||
| Q3 24 | $3.4M | $4.3M | ||
| Q2 24 | — | $1.3M |
| Q1 26 | 10.8% | — | ||
| Q4 25 | — | 72.5% | ||
| Q3 25 | 11.1% | 73.3% | ||
| Q2 25 | 12.0% | 71.7% | ||
| Q1 25 | 10.0% | 72.1% | ||
| Q4 24 | — | 72.0% | ||
| Q3 24 | 11.3% | 71.3% | ||
| Q2 24 | — | 71.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.3% | ||
| Q3 25 | 1.4% | 7.0% | ||
| Q2 25 | 1.9% | 3.7% | ||
| Q1 25 | — | 5.4% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | 4.0% | 4.6% | ||
| Q2 24 | — | 5.1% |
| Q1 26 | 2.2% | — | ||
| Q4 25 | — | 3.3% | ||
| Q3 25 | 4.4% | 4.2% | ||
| Q2 25 | 5.2% | 4.6% | ||
| Q1 25 | 19.6% | 4.2% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | 2.1% | 3.8% | ||
| Q2 24 | — | 1.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.23 | ||
| Q3 25 | — | $0.30 | ||
| Q2 25 | — | $0.28 | ||
| Q1 25 | — | $0.25 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $0.23 | ||
| Q2 24 | — | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $561.1M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $161.6M |
| Total Assets | $1.3B | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $561.1M | — | ||
| Q4 25 | — | $93.9M | ||
| Q3 25 | $628.6M | $95.6M | ||
| Q2 25 | $499.4M | $81.3M | ||
| Q1 25 | $592.4M | $86.5M | ||
| Q4 24 | — | $84.7M | ||
| Q3 24 | $517.4M | $78.7M | ||
| Q2 24 | — | $68.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | $161.6M | ||
| Q3 25 | — | $166.7M | ||
| Q2 25 | — | $163.7M | ||
| Q1 25 | — | $167.1M | ||
| Q4 24 | — | $161.0M | ||
| Q3 24 | — | $162.6M | ||
| Q2 24 | — | $156.4M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | $261.1M | ||
| Q3 25 | $1.3B | $264.8M | ||
| Q2 25 | $1.2B | $254.9M | ||
| Q1 25 | $1.2B | $252.7M | ||
| Q4 24 | — | $240.9M | ||
| Q3 24 | $926.8M | $245.3M | ||
| Q2 24 | — | $235.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $9.9M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.1% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $9.9M | ||
| Q3 25 | — | $18.5M | ||
| Q2 25 | — | $4.3M | ||
| Q1 25 | — | $2.6M | ||
| Q4 24 | — | $12.2M | ||
| Q3 24 | — | $9.6M | ||
| Q2 24 | — | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $7.6M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $1.5M | ||
| Q4 24 | — | $10.0M | ||
| Q3 24 | — | $7.9M | ||
| Q2 24 | — | $-2.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.1% | ||
| Q3 25 | — | 13.1% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 1.3% | ||
| Q4 24 | — | 8.5% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | -1.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 3.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.41× | ||
| Q3 25 | — | 3.46× | ||
| Q2 25 | — | 0.81× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.21× | ||
| Q2 24 | — | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLX
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
